The New Coronavirus Rapid Test is currently the "gold standard" for the diagnosis of New Coronavirus. When the Nucleic Acid Rapid Test is positive, and the Nucleic Acid Rapid Test is still positive, the diagnosis of NIV infection is confirmed.
In the Nucleic Acid Rapid Test, fluorescence is used to report whether a test is positive or not, and different colors of fluorescence represent a target. A commonly used rapid test for neointestinal nucleic acid uses fluorescent quantitative PCR to fluorescently label the ORF1ab and N genes on neointestinal nucleic acid.
When both targets report fluorescence signals a positive output is given, when only one reports fluorescence signals, a single gene is positive.
Generally, positive patients will have both ORF1ab and N gene positivity, but they may also have one positive ORF1ab or N gene, which is called single positive. When a single positive test is found, it is not possible to confirm whether or not the patient is infected with the New Coronavirus, and it is necessary to take another sample for retesting and combine the results with epidemiological history, clinical manifestations, antibody testing, and imaging examinations to make a comprehensive decision.
So if there is a single positive Nucleic Acid Rapid Test, does it mean that the Nucleic Acid Rapid Test is not accurate?
No! The two targets are actually set to make the test more accurate. Two targets means that there will be two indicators to confirm infection in the nucleic acid test.
A single positive result for the Nucleic Acid Rapid Test means that the two targets that are supposed to give the same answer report different answers.
When two targets give different answers, it indicates possible interference in the New Crown Nucleic Acid Rapid Test procedure. There are several challenges such as cross contamination, temperature edge effects, fluorescence detection channel crosstalk, etc. that may occur during automated nucleic acid extraction assays, all of which may lead to abnormal New Crown nucleic acid rapid test results.
In response to the above possibilities that may lead to abnormal results of rapid nucleic acid testing of new crown, leading domestic companies and R&D teams have developed technologies with core patents, which have also been certified by WHO, EU CE, etc., and can greatly solve the above problems and provide an accurate basis for nucleic acid testing of new crown virus.
In addition, in emergency places often use the new crown nucleic acid rapid test equipped with college amplification reagents and portable amplification equipment to quickly triage patients, once the new crown nucleic acid rapid test reports a positive result, it will be immediately isolated for further more sensitive testing.
